Get the Stockscreener App
28.05
5.27%
1.405
Tvardi Therapeutics Inc stock is traded at $28.05, with a volume of 42,712.
It is up +5.27% in the last 24 hours and up +10.56% over the past month.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
See More
Previous Close:
$26.64
Open:
$27.11
24h Volume:
42,712
Relative Volume:
0.77
Market Cap:
$262.57M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+16.88%
1M Performance:
+10.56%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$26.73
$29.00
1-Week Range:
$23.79
$29.00
52-Week Range:
$15.80
$34.31
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
28.05 | 231.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
Is Tvardi Therapeutics Inc. stock poised for growthIndex Update & Reliable Price Breakout Alerts - Newser
Tvardi Therapeutics Inc. Approaches Support With Recovery in SightMarket Trend Review & Capital Efficiency Focused Strategies - classian.co.kr
Tvardi Therapeutics Inc. stock chart pattern explained2025 Support & Resistance & Risk Managed Investment Strategies - Newser
Relative strength of Tvardi Therapeutics Inc. in sector analysisGDP Growth & Community Verified Trade Signals - Newser
What technical models suggest about Tvardi Therapeutics Inc.’s comeback2025 Earnings Impact & Technical Pattern Recognition Alerts - Newser
Ranking Tvardi Therapeutics Inc. among high performing stocks via toolsDay Trade & Free Weekly Watchlist of Top Performers - Newser
Visual trend scoring systems applied to Tvardi Therapeutics Inc.GDP Growth & Weekly Top Gainers Trade List - Newser
Should you wait for a breakout in Tvardi Therapeutics Inc.Inflation Watch & Real-Time Buy Signal Alerts - Newser
Tools to assess Tvardi Therapeutics Inc.’s risk profileWeekly Gains Report & Expert Approved Trade Ideas - Newser
How sentiment analysis helps forecast Tvardi Therapeutics Inc.2025 Key Lessons & Growth Focused Entry Reports - Newser
Is Tvardi Therapeutics Inc. meeting your algorithmic filter criteriaQuarterly Earnings Summary & Stepwise Entry/Exit Trade Alerts - Newser
Can machine learning forecast Tvardi Therapeutics Inc. recovery2025 Institutional Moves & Fast Gaining Stock Strategy Reports - Newser
Tvardi Therapeutics Reports Q2 2025 Financial Results - TipRanks
Tvardi Therapeutics Faces Legal and Financial Risks from Exclusive Forum Provision - MSN
Real time social sentiment graph for Tvardi Therapeutics Inc.2025 Market Trends & Community Consensus Stock Picks - Newser
Is Tvardi Therapeutics Inc. trending in predictive chart modelsMarket Risk Analysis & Consistent Profit Trading Strategies - Newser
How institutional ownership impacts Tvardi Therapeutics Inc. stockProduct Launch & High Win Rate Trade Alerts - Newser
Why is Tvardi Therapeutics Inc. stock going upJuly 2025 Review & Community Consensus Trade Alerts - sundaytimes.kr
Top chart patterns to watch in Tvardi Therapeutics Inc.Watch List & Safe Capital Investment Plans - Newser
Will Tvardi Therapeutics Inc. stock go up soonJuly 2025 PostEarnings & Weekly Hot Stock Watchlists - Newser
Volatility clustering patterns for Tvardi Therapeutics Inc.Portfolio Performance Summary & Fast Moving Trade Plans - Newser
Building trade automation scripts for Tvardi Therapeutics Inc.Weekly Trend Summary & Safe Capital Growth Plans - Newser
How to build a custom watchlist for Tvardi Therapeutics Inc.Quarterly Market Summary & Technical Pattern Recognition Alerts - Newser
Can technical indicators confirm Tvardi Therapeutics Inc.’s reversalJuly 2025 Recap & Low Risk Growth Stock Ideas - Newser
Tvardi Posts Q2 Net Income Turnaround - AOL.com
Tvardi: Q2 Earnings Snapshot - Greenwich Time
Tvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last year - TipRanks
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
There is no financial data for Tvardi Therapeutics Inc (TVRD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Tvardi Therapeutics Inc Stock (TVRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):